MeiraGTx Holdings (MGTX) Accumulated Expenses (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Accumulated Expenses came in at $32.9 million in Q4 2025, up 19.99% YoY from $27.4 million in Q4 2024, and up 37.79% on a QoQ basis from $23.9 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Accumulated Expenses (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Accumulated Expenses data on file, last reported at $32.9 million in Q4 2025.
- Quarterly Accumulated Expenses rose 19.99% year-over-year to $32.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $32.9 million (up 19.99% YoY) and the FY2025 annual result came in at $32.9 million, up 19.99% from the prior year.
- Accumulated Expenses rose to $32.9 million in Q4 2025, from $23.9 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $42.6 million in Q4 2023 to a low of $15.5 million in Q2 2025.
- A 5-year average of $25.0 million and a median of $23.9 million in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 44.34% — and 2024, when it tumbled 44.14%.
- Tracing MGTX's Accumulated Expenses over 5 years: stood at $27.6 million in 2021, then soared by 44.34% to $39.8 million in 2022, then climbed by 7.08% to $42.6 million in 2023, then slumped by 35.71% to $27.4 million in 2024, then rose by 19.99% to $32.9 million in 2025.
- The last three Accumulated Expenses figures came in at $32.9 million (Q4 2025), $23.9 million (Q3 2025), and $15.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.23 Mn |
| Dec 31, 2025 | 32.89 Mn |
| Sep 30, 2025 | 23.87 Mn |
| Jun 30, 2025 | 15.48 Mn |
| Mar 31, 2025 | 23.96 Mn |
| Dec 31, 2024 | 27.41 Mn |
| Sep 30, 2024 | 19.34 Mn |
| Jun 30, 2024 | 16.93 Mn |
| Mar 31, 2024 | 17.35 Mn |
| Dec 31, 2023 | 42.64 Mn |
| Sep 30, 2023 | 28.25 Mn |
| Jun 30, 2023 | 24.89 Mn |
| Mar 31, 2023 | 31.07 Mn |
| Dec 31, 2022 | 39.82 Mn |
| Sep 30, 2022 | 24.77 Mn |
| Jun 30, 2022 | 23.57 Mn |
| Mar 31, 2022 | 23.18 Mn |
| Dec 31, 2021 | 27.59 Mn |
| Sep 30, 2021 | 21.93 Mn |
| Jun 30, 2021 | 17.56 Mn |